Published online before print October 11, 2004, doi: 10.1161/01.HYP.0000145988.95551.28
(Hypertension. 2004;44:789.)
© 2004 American Heart Association, Inc.
Brief Review |
Hormone Replacement Therapy and Cardiovascular Disease
What Went Wrong and Where Do We Go From Here?
From the Center for Clinical Pharmacology (R.K.D., B.I., C.Z.L., E.K.J.), Departments of Medicine (R.K.D., C.Z.L., E.K.J.) and Pharmacology (E.K.J.), University of Pittsburgh Medical Center, Pittsburgh, Pa; University Hospital Zurich (R.K.D., B.I.), Department of Obstetrics and Gynecology, Clinic for Endocrinology, Zurich, Switzerland.
Correspondence to Dr Raghvendra K. Dubey, Clinic for Endocrinology (D217, NORD-1), Department of Obstetrics and Gynecology, University Hospital Zurich, Frauenklinikstrasse 10, CH-8051, Zurich, Switzerland. E-mail Raghvendra.dubey{at}usz.ch
Observational studies in humans and experimental studies in animals and isolated cells supported the widely held belief that hormone replacement therapy protects the cardiovascular system from disease. To nearly everyone’s astonishment, the Women’s Health Initiative Study and the Heart and Estrogen/Progestin Replacement Study overturned the conclusion that hormone replacement therapy protects the cardiovascular system and, in fact, supported the opposite view that such therapy may actually increase the risk of cardiovascular disease. This review addresses 2 questions: what went wrong and where do we go from here?
Key Words: estrogen • hormones • cardiovascular diseases
This article has been cited by other articles:
 |
|
 |
|
  X. Fan, Y. Han, K. Sun, Y. Wang, Y. Xin, Y. Bai, W. Li, T. Yang, X. Song, H. Wang, et al. Sex Differences in Blood Pressure Response to Antihypertensive Therapy in Chinese Patients with Hypertension Ann. Pharmacother., December 1, 2008; 42(12): 1772 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bourghardt, G. Bergstrom, A. Krettek, S. Sjoberg, J. Boren, and A. Tivesten The Endogenous Estradiol Metabolite 2-Methoxyestradiol Reduces Atherosclerotic Lesion Formation in Female Apolipoprotein E-Deficient Mice Endocrinology, September 1, 2007; 148(9): 4128 - 4132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Denton and C. Baylis Physiological and molecular mechanisms governing sexual dimorphism of kidney, cardiac, and vascular function Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R697 - R699. [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. Schulman, P. Aranda, L. Raij, M. Veronesi, F. J. Aranda, and R. Martin Surgical Menopause Increases Salt Sensitivity of Blood Pressure Hypertension, June 1, 2006; 47(6): 1168 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Fu and B. D. Levine Hypertension and Antihypertensive Therapy in Elderly Women: How Much Do We Really Know? Hypertension, March 1, 2006; 47(3): 323 - 324. [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Mayer, C. A. Dyer, R. L. Eastgard, P. B. Hoyer, and C. L. Banka Atherosclerotic Lesion Development in a Novel Ovary-Intact Mouse Model of Perimenopause Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1910 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Khalil Sex Hormones as Potential Modulators of Vascular Function in Hypertension Hypertension, August 1, 2005; 46(2): 249 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. O. Ventura and M. R. Mehra The Interaction of Vascular Stiffness and Cardiovascular Events in Women: Insights From the Heart and Estrogen/Progestin Replacement Study Chest, May 1, 2005; 127(5): 1477 - 1480. [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Dubey, B. Imthurn, M. Barton, and E. K. Jackson Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen Cardiovasc Res, May 1, 2005; 66(2): 295 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, January 15, 2005; 330(7483): 154 - 154. [Full Text] [PDF]
|
|